| Identification | Back Directory | [Name]
L-Valine, N-acetyl-L-alanyl-, methyl ester (9CI) | [CAS]
99141-91-0 | [Synonyms]
Ac-Ala-Val-OMe
L-Valine, N-acetyl-L-alanyl-, methyl ester (9CI) | [Molecular Formula]
C11H20N2O4 | [MOL File]
99141-91-0.mol | [Molecular Weight]
244.29 |
| Chemical Properties | Back Directory | [Melting point ]
105 °C | [Boiling point ]
442.1±25.0 °C(Predicted) | [density ]
1.078±0.06 g/cm3(Predicted) | [storage temp. ]
-10 to -25°C | [solubility ]
Soluble to 100 mM in ethanol and to 100 mM in DMSO | [form ]
Oil | [pka]
13.30±0.46(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
ZZL-7 is a fast-onset antidepressant agent. ZZL-7 works by disrupting the interaction between the serotonin transporter (SERT) and neuronal nitric oxide synthase (nNOS) in the dorsal raphe nucleus (DRN). ZZL-7 can cross the blood-brain barrier readily. ZZL-7 can be used for the research of major depressive disorder (MDD)[1]. | [Biological Activity]
ZZL-7 is a fast-acting antidepressant that enhances 5-HT (serotonin) signaling in forebrain circuits. ZZL-7 disrupts the interaction between the 5-HT transporter (SERT) and neuronal nitric oxide synthase (nNOS) in the dorsal raphe nucleus (DRN), which reduces extracellular 5-HT concentration and down-regulates 5-HT1A receptor auto-activity in the DRN. This reduced auto-inhibition enables increase in firing frequency of serotonergic neurons in the DRN and increases in 5-HT release in the medial hippocampus. ZZL-7 can readily cross the blood-brain barrier. | [in vivo]
ZZL-7 (10 mg/kg, intraperitoneally) causes significantly increases firing frequency of serotonergic neurons 2 hours after treatment in vivo electrophysiology in SERT-Cre mice. In wild-type mice, ZZL-7 reduces immobility time[1].
Intragastric administration of ZZL-7 (10, 20, and 40 mg/kg; once) produces antidepressant-like behaviors dose dependently 2 hours after treatment[1].
ZZL-7 (10 mg/kg; intraperitoneal administration) reverses chronic unpredictable mild stress (CMS)-induced depressions behaviors 2 hours after treatment[1]. | Animal Model: | SERT-Cre mice[1] | | Dosage: | 10 mg/kg | | Administration: | i.p.; once | | Result: | Significantly increased firing frequency of serotonergic neurons 2 hours after treatment in vivo electrophysiology in SERT-Cre mice. |
| [storage]
Store at -20°C | [References]
[1] Nan Sun, et al. Design of fast-onset antidepressant by dissociating SERT from nNOS in the DRN. Science. 2022 Oct 28;378(6618):390-398. DOI:10.1126/science.abo3566 |
|
| Company Name: |
Merck KGaA
|
| Tel: |
21-20338288 |
| Website: |
www.sigmaaldrich.cn |
|